Bibliography for: "Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis"

Philippe Andres "Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis". Journal of Drugs in Dermatology. FindArticles.com. 06 Jan, 2010. http://findarticles.com/p/articles/mi_m0PDG/is_4_5/ai_n16361309/

Journal of Drugs in Dermatology

View more issues:

Articles in April, 2006 issue of Journal of Drugs in Dermatology

• Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens
  by Joseph W. Stanfield
• Uncontrollable prurigo nodularis effectively treated by roxithromycin and tranilast
  by Yasuhiro Horiuchi
• GSK to seek FDA approval for HPV vaccine Cervarix
  by Monika Srivastava
• Pegylated interferon-alpha-2a in patients with malignant melanoma stage IIA-IIIB
• The effect of 0.5% roxithromycin lotion for androgenetic alopecia
• Alefacept in the treatment of psoriatic nail disease: a proof of concept study
  by Charles A. Parrish
• The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial
  by Isaac Brownell
• Vusion approved by the FDA for diaper dermatitis complicated by candidiasis
  by Monika Srivastava
• Study of cetuximab in squamous cell carcinoma of the skin expressing EGFR
• Comparison of excision versus punch incision in the treatment of epidermal cysts
• Topical NF-kappa B Decoy in the treatment of atopic dermatitis
• Study of ONTAK in cutaneous T-cell lymphoma patients
• An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis
  by Karl Beutner
• Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris
  by Isaac Brownell
• CYA versus MMF for treatment of moderate to severe psoriasis
• Ultraviolet B light therapy in the treatment of skin conditions with altered dermal matrix
• Efficacy and safety of calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris
• Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid
  by A. Kasche
• Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
  by Isaac Brownell
• Schools of Pharmacology
  by Noah Scheinfeld
• Study of the efficacy, safety and tolerability of oral CEP-701 in patients with severe psoriasis
• Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques
  by G. Martin Ezquerra
• Nicolau syndrome: a report of 2 cases
  by Sharad Mutalik
• Gardasil to receive priority review from FDA
  by Monika Srivastava
• Immunopharmacological effects of Rituximab in atopic dermatitis
• Study of ONTAK in previously treated cutaneous T-cell lymphoma patients
• Common allergens in skin tests for adult atopic dermatitis
• Intralesional treatment with interleukin-2 in soft tissue melanoma metastases
• Recurrent injection site reactions from interferon beta 1-b
  by Lena Samuel
• FDA considers postponing deadline for iPledge program
  by Monika Srivastava
• Treatment of melasma with Jessner's solution versus trichloroacetic acid
• Curcuminoids for the treatment of chronic psoriasis vulgaris
• Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis
  by Philippe Andres
• Dapsone in the treatment of persistent erythema multiforme
  by Laura D. Hoffman
• Garenoxacin accepted for FDA review
  by Monika Srivastava
• Phase IV study to gather more information about the safety of ACZONE Gel 5% in treating subjects with acne who have G6PD deficiency
• Etanercept for treatment of hidradenitis
• The utility of benzoyl peroxide in hydrophase base in the treatment of acne vulgaris
  by Jeffrey M. Weinberg
• A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris
  by Isaac Brownell
• FDA mandates new warnings for Tequin
  by Monika Srivastava
• Efficacy and safety of calcipotriol plus betamethasone dipropionate ointment in patients with psoriasis vulgaris
• Standard palliative care versus standard palliative care plus polychemotherapy in metastasized malignant melanoma
• Efficacy of elidel cream on erosive oral lichen planus
• Standard high-dose alpha interferon versus intermittent high-dose alpha interferon
• Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?
  by Jane Yoo
• Epidermal growth factor receptor inhibitor associated skin eruption
  by Elizabeth V. Seiverling
• FDA approves Clarinex-D® 12 Hour
  by Monika Srivastava
• A phase II randomized study of ACZONE gel 5% for papulopustular rosacea
• Safety and efficacy study of MM-093 in patients with chronic plaque psoriasis
• Efficacy study of latanoprost and bimatoprost solutions in promoting eyelash growth in patients with alopecia areata
• Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency
  by M.B. Abdel-Naser
• GlaxoSmithKline's topical antibiotic retapamulin accepted for FDA review
  by Monika Srivastava
• Imatinib in dermatofibrosarcoma protuberans
• A study of the use of methotrexate in the treatment of chronic idiopathic urticaria
• The impact of treating staphylococcus aureus infection and colonization on the clinical severity of atopic dermatitis